{"success":true,"data":{"pressRelease":{"id":"172630","rtpr_id":"nGNX5ZCv1h-20261019","ticker":"INDV","exchange":"NASDAQ","all_tickers":["INDV"],"title":"Indivior to Report Third Quarter 2026 Financial Results","author":"Globe Newswire","published_at":"2026-10-19T12:30:00.812Z","article_body":"RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals,\nInc. (Nasdaq: INDV) today announced that it will report its third quarter 2026\nfinancial results on Thursday, October 29, 2026. The results will be released\nat 7:00 a.m. U.S. EDT and will be available on the Company’s website at\nwww.indivior.com.\n\nAbout Indivior\n\nAs the leader in long-acting injectable treatments for opioid use disorder\n(OUD), Indivior is singularly focused on delivering evidence-based treatment\nand advancing understanding of OUD as a chronic but treatable brain disease.\nFor more than 25 years, we have revolutionized the science of addiction\nmedicine — developing treatments that help people move toward long-term\nrecovery with independence and dignity. Building on this heritage, we are\nushering in a new era, renewing our commitment to individuals living with OUD\nand carrying forward what matters most: compassion, integrity, and science.\nTogether – with science, people living with OUD, public health champions,\nand communities, we are powering recovery and renewing hope. Visit\nwww.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting\nwww.linkedin.com/company/Indivior.\n\nFor Further Information:\n\n Investors  Jason Thompson       VP, Investor Relations  +1 804 402 7123 jason.thompson@indivior.com         \n Media      Cassie France-Kelly  VP, Communications      +1 804 594 0836 Indiviormediacontacts@indivior.com  \n\n\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5ZCv1h-20261019","title":"Indivior to Report Third Quarter 2026 Financial Results","author":"Globe Newswire","ticker":"INDV","created":"2026-10-19T12:30:00.812Z","tickers":["INDV"],"exchange":"NASDAQ","article_body":"RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals,\nInc. (Nasdaq: INDV) today announced that it will report its third quarter 2026\nfinancial results on Thursday, October 29, 2026. The results will be released\nat 7:00 a.m. U.S. EDT and will be available on the Company’s website at\nwww.indivior.com.\n\nAbout Indivior\n\nAs the leader in long-acting injectable treatments for opioid use disorder\n(OUD), Indivior is singularly focused on delivering evidence-based treatment\nand advancing understanding of OUD as a chronic but treatable brain disease.\nFor more than 25 years, we have revolutionized the science of addiction\nmedicine — developing treatments that help people move toward long-term\nrecovery with independence and dignity. Building on this heritage, we are\nushering in a new era, renewing our commitment to individuals living with OUD\nand carrying forward what matters most: compassion, integrity, and science.\nTogether – with science, people living with OUD, public health champions,\nand communities, we are powering recovery and renewing hope. Visit\nwww.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting\nwww.linkedin.com/company/Indivior.\n\nFor Further Information:\n\n Investors  Jason Thompson       VP, Investor Relations  +1 804 402 7123 jason.thompson@indivior.com         \n Media      Cassie France-Kelly  VP, Communications      +1 804 594 0836 Indiviormediacontacts@indivior.com  \n\n\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-19T12:30:00.948549171Z","server_sent_at_ms":1792413000948},"received_at":"2026-10-19T12:30:00.998Z","source_url":null},"analysis":{"id":"160743","press_release_id":"172630","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Indivior announced it will report third quarter 2026 financial results on Thursday, October 29, 2026.\n\nThe release will go out at 7:00 a.m. U.S. EDT and be available on the company's website; no results or guidance were included in this notice.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Earnings-date notice only — mark calendar, no post needed until results."},"keyFigures":{},"namedEntities":{"people":[{"name":"Jason Thompson","role":"VP, Investor Relations"},{"name":"Cassie France-Kelly","role":"VP, Communications"}],"products":[],"companies":[{"name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate earnings-date notice with no results, guidance, or other financial content. Routine scheduling announcement only."},"tickerRelevance":{"others":[],"primary":"INDV"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"noResults":true,"tickerTier":"small/mid-cap pharma","eventGravity":"earnings-date-notice"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Indivior announced it will report third quarter 2026 financial results on Thursday, October 29, 2026.\n\nThe release will go out at 7:00 a.m. U.S. EDT and be available on the company's website; no results or guidance were included in this notice.","key_figures":{},"named_entities":{"people":[{"name":"Jason Thompson","role":"VP, Investor Relations"},{"name":"Cassie France-Kelly","role":"VP, Communications"}],"products":[],"companies":[{"name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-19T12:30:11.497Z","global_importance":10,"audience_relevance":15,"importance_components":{"noResults":true,"tickerTier":"small/mid-cap pharma","eventGravity":"earnings-date-notice"}},"durationMs":3413,"modelName":"glm-5.3-flashx"}}